PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Infex candidate nominated for COV-X programme

Therapy targets the coronavirus PLPRO enzyme essential for the evasion of host immune response.

Infex Therapeutics, a company focusing on anti-infectives, has revealed the nomination of a candidate for its COV-X programme.

The candidate for COV-X – Infex’s novel first-in-class small molecule oral pan-coronavirus PLPRO inhibitor – was chosen after in vivo efficacy data emerged in a murine SARS-CoV-2 model that showed an almost complete decrease in SARS-CoV-2 viral load in the lungs.

Meanwhile, it also delivered a sound safety profile when compared to nirmatrelvir, Pfizer’s approved MPRO inhibitor.

In contrast to nirmatrelvir, COV-X targets the key coronavirus PLPRO enzyme. This enzyme is essential for viral replication and evasion of host immune response. Consequently, COV-X has the potential for spectrum efficacy against new coronaviruses or variants, which have the risk of widening into a pandemic.

In recent weeks, the development of new SARS-CoV-2 variants – resistant to nirmatrelvir – has been reported. Infex’s COV-X programme potentially offers an alternative for treating resistant strains, either as a stand-alone therapy or when combined with MPRO drugs.

Dr Peter Jackson, chief executive officer at Infex Therapeutics, was encouraged by the candidate data: “With global SARS-CoV-2 vaccines showing increasing weakness against new variants, it will be essential to develop effective broad-spectrum antivirals that can future-proof against new coronaviruses with pandemic potential.”

He added: “Following encouraging pre-clinical data in comparison with Pfizer’s MPRO inhibitor nirmatrelvir, we have high hopes for our nominated candidate for our COV-X programme. COV-X demonstrated superior efficacy and DMPK profile to nirmatrelvir, and its ability to reduce viral load in the lungs is key to minimising the chances of long-term viral conditions, such as long COVID.

“Given COV-X’s outstanding profile and potential value, we are now seeking a global pharmaceutical partner to accelerate its development towards commercialisation.”

Having delivered a pre-clinical candidate, COV-X is currently undertaking further research to provide a comprehensive safety profile ahead of clinical stage development.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026